PDCD1 and colorectal carcinoma: In one trial (NCT03927898) combining toripalimab (anti-PD-1) together with stereotactic body radiotherapy for the treatment of oligometastatic CRC, investigators will analyze dynamic TCR repertoire changes in peripheral blood as well as PD-1 and Ki67 expression on T cells and PD-L1 expression on circulating tumor cells.